- Description
- Product Info
- Shipping and Storage
- Downloads
- References
Description
Ensartinib is a third-generation ALK inhibitor. In addition, ensartinib is found to also have activity against ROS1, MET, SLK, Axl, LTK, ABL and EPHA2.
Product Info
1365267-27-1 |
≥98% |
C25H25Cl2FN6O3 |
547.41 |
6-amino-5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-N-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide |
X396, X-396 |
Shipping and Storage
-20°C |
Ambient |
Downloads
E543721 Info Sheet PDF |
References
Horn L, Wakelee H, Reckamp KL, et al. MINI01.02: Response and plasma genotyping from phase I/II trial of ensartinib (X-396) in patients (pts) with ALK+ NSCLC: topic: medical oncology. J Thorac Oncol. 2016 Nov;11(11S)::S256-S257. PMID: 27969449
Caccese M, Ferrara R, Pilotto S, et al. Current and developing therapies for the treatment of non-small cell lung cancer with ALK abnormalities: update and perspectives for clinical practice. Expert Opin Pharmacother. 2016 Dec;17(17):2253-2266. PMID: 27682212
Dholaria B, Hammond W, Shreders A, et al. Emerging therapeutic agents for lung cancer. J Hematol Oncol. 2016 Dec 9;9(1):138. PMID: 27938382
本文链接： http://lkt.immuno-online.com/view-1546577720.html
